Form 4: Adial Pharmaceuticals CEO Cary J. Claiborne Acquires Stock Options
SEC Form 4 Filing
Cary J. Claiborne, CEO of Adial Pharmaceuticals, acquired 60,000 stock options on March 25, 2024.
Summary
- On March 25, 2024, Cary J. Claiborne, the CEO of Adial Pharmaceuticals, acquired 60,000 stock options.
- The options have an exercise price of $1.35.
- The options vest pro rata on a monthly basis over 36 months, starting April 25, 2024.
- The options expire on March 24, 2034.
- Following the transaction, Mr. Claiborne beneficially owns 60,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral report of an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their holdings in the company's stock.
Stakeholder Impact
- Shareholders may view this transaction as a sign of confidence from the CEO in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of earliest transaction: CEO Cary J. Claiborne acquired stock options. |
| 03/25/2024 | Transaction Date: Stock options acquired. |
| 04/25/2024 | Vesting start date for the stock options. |
| 03/24/2034 | Expiration date for the stock options. |
| 03/27/2024 | Date of Form 4 signature. |
Keywords
stock options, Form 4, Adial Pharmaceuticals, ADIL, Cary J. Claiborne, CEO, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.